Tribune News Service
Rohtak, September 7
Following the success of the primary section of scientific human trials of India’s indigenous COVID vaccine, Covaxin, medical specialists at Rohtak PGIMS will start screening the volunteers for the second section of the trials on Monday.
“In the first phase, two doses of Covaxin were given to 375 healthy volunteers in the age-group of 18 to 55 years across the country, of whom 81 were administered the vaccine at Rohtak PGIMS. In the second phase, we will give two doses of the vaccine to new volunteers in the age-group of 12 to 65 years. Nearly 250 volunteers have registered with us for the trials, and their screening will begin today,” Dr Ramesh Verma, co-investigator within the mission advised The Tribune.
He disclosed that whereas solely wholesome volunteers had been concerned within the first section of trials, the volunteers who’ve managed diabetes, hypertension or bronchial asthma and so on may even be concerned within the second section.
The well being investigator maintained that the permission to conduct the second section of trials is granted after a four-fold improve is recorded in COVID antibodies within the blood samples of the volunteers who had been given doses of Covaxin within the first section.
“In the first phase, the volunteers were given two doses of the vaccine on Day 1 and Day 14. In the second phase, they will be administered the vaccine on Day 1 and Day 28,” he added.